1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc.

ACUR
Acura Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
6,600.00Market Cap
Acura Pharmaceuticals, Inc.
ACUR
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
FRC
- -
0.82
4.86
0.42
0.35
2.15
- -
0.01
0.08
0.8
0.38
0.19
0.02
0.1
0.11
0.03
0.03
Revenue per Share
-0.86
-0.55
1.58
-1.72
-1.35
1.09
-1.02
-1.46
-1.35
-0.46
-0.62
-0.36
-0.18
-0.14
-0.04
-0.02
-0.02
Basic EPS, GAAP
-0.79
2.45
0.46
-0.57
-0.69
1.28
-0.76
-1.43
-1.35
-0.36
-0.47
-0.28
-0.18
-0.02
-0.02
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-5.78
2.19
4.34
3.42
2.77
4.04
3.01
1.85
0.52
0.67
0.1
- -
-0.17
-0.22
-0.27
- -
- -
Book Value per Share
-5.78
2.19
4.34
3.42
2.77
4.04
3.01
1.85
0.33
0.53
-0.02
-0.06
-0.22
-0.26
-0.28
- -
- -
Tangible Book Value per Share
7
8
9
9
9
10
10
10
10
11
12
16
21
27
32
57
57
Basic Weighted Avg Shares
- -
6
44
4
3
20
- -
- -
1
9
4
3
- -
3
4
2
2
Sales/Revenue/Turnover
- -
-76.61
47.22
-352.02
-384.29
51.47
- -
-11,455.28
-1,624.37
-46.59
-146.89
-176.16
-954.88
-27.29
-21.23
-77.67
-77.67
Operating Margin (%)
- -
3
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-6
-4
14
-16
-13
10
-10
-14
-13
-5
-7
-6
-4
-4
-1
-1
-1
Net Income, GAAP
- -
- -
33.48
- -
- -
1.4
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-67.36
32.57
-412.91
-383.78
50.74
- -
-11,301.63
-1,758.85
-58.1
-165.5
-191.57
-937.07
-142.04
-33.84
-56.24
-56.24
Profit Margin (%)
-29
22
36
29
23
36
27
26
10
11
2
-2
-1
- -
-6
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
10
8
5
3
- -
4
6
- -
- -
- -
LT Debt
-38
19
37
30
24
37
28
18
5
8
1
- -
-4
-5
-6
- -
- -
Total Equity
- -
- -
50.04
- -
- -
34.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
51.89
- -
- -
34.06
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
234.53
Return on Capital (%)
- -
- -
51.89
-47.29
-46.85
34.06
-30.08
-61.03
-114.99
-77.04
-162.68
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'21
Sep'21
Dec'21
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
65
65
65
Market Capitalization
43
34
33

Working Capital

FRC

•

in mil. unless spec.
Jun'21
Sep'21
Dec'21
Total Current Assets
1
1
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
1
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1,298.61%
2,629.27%
-103.02%
Free Cash Flow
-19.6%
-19.6%
3.2%
Net Income, GAAP
-32.09%
-30.49%
-27.24%
Sales/Revenue/Turnover
- -
81.29%
-56.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
1
1
3
2020
1
1
- -
1
4
2021
1
1
- -
- -
2

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
-0.04
-0.15
0.01
- -
-0.14
2020
-0.02
0.01
-0.02
- -
-0.04
2021
-0.01
-0.01
- -
- -
-0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
Similar Companies
Cronos Group Inc. (CRON.TO)
Zydus Lifesciences Limited (CADILAHC.NS)
Endo International plc (ENDP)
Acorda Therapeutics, Inc. (ACORQ)
Hanmi Pharm. Co., Ltd. (128940.KS)
AptaBio Therapeutics Inc. (293780.KQ)
Business
Acura Pharmaceuticals, Inc. (ACUR) develops and commercializes proprietary drug delivery technologies designed to deter medication abuse, misuse, and overdose, including its LIMITx, Aversion, and Impede platforms; LIMITx retards active drug release upon intentional or accidental ingestion of multiple tablets by neutralizing stomach acid with buffers while delivering normal therapeutic levels from single doses, as in lead candidate LTX-03 (hydrocodone bitartrate/acetaminophen); Aversion incorporates gelling agents and nasal irritants to thwart snorting and injection abuse, powering the FDA-approved OXAYDO tablets (oxycodone HCl, CII) in 5mg and 7.5mg strengths licensed to Zyla Life Sciences; and Impede resists pseudoephedrine extraction for methamphetamine conversion, featured in Nexafed (pseudoephedrine HCl 30mg) and Nexafed Sinus Pressure + Pain (pseudoephedrine HCl/acetaminophen 30/325mg) marketed by MainPointe Pharmaceuticals in the United States and Canada. Founded in 1935 and headquartered in Palatine, Illinois, the company targets the U.S. pharmaceutical market, focusing on opioid analgesics, pseudoephedrine products, and abuse-deterrent formulations for prescribers, pharmacies, and patients seeking safer medication options. In recent developments, Acura has secured multiple loans from Abuse Deterrent Pharma LLC (AD Pharma), which controls about 65% of its common stock, pushing total principal owed to approximately $9 million as of October 2025 with 5.25% interest maturing variably through early 2026, amid ongoing operational funding needs that risk scaling back, furloughs, or termination absent further capital; LTX-03 U.S. commercialization rights are exclusively licensed to AD Pharma, with the latest amendment (effective May 2025) extending the FDA New Drug Application acceptance deadline to December 31, 2025, while the FDA requires additional data plans for lower strengths.

Company News

APIChatGPT

  • defenseworld.net

    Acura Pharmaceuticals (OTCMKTS:ACUR) Shares Pass Above Two Hundred Day Moving Average – Should You Sell?

  • globenewswire.com

    Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results